We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01196923
First Posted: September 9, 2010
Last Update Posted: July 27, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
CardioFocus
September 7, 2010
September 9, 2010
April 18, 2016
July 27, 2016
July 27, 2016
September 2010
March 2012   (Final data collection date for primary outcome measure)
Acute Isolation of Pulmonary Veins. [ Time Frame: Acute PVI measured on the day of treatment ]
99% of pulmonary veins were isolated (72/73)
To determine the EAS-AC treatment success rate defined as the freedom from documented atrial fibrillation symptoms during the 12-month evaluation period. [ Time Frame: 12 Months ]
Complete list of historical versions of study NCT01196923 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
The purpose of this study is to confirm the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact in the treatment of atrial fibrillation.
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Atrial Fibrillation
Device: Endoscopically Guided Ablation
Visually Guided Ablation using EAS-AC
Experimental: HeartLight Ablation
Intervention: Device: Endoscopically Guided Ablation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
June 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptomatic, Paroxysmal Atrial Fibrillation (AF)
  • 18 to 70 Years of age
  • Others

Exclusion Criteria:

  • Generally good overall health as determined by multiple criteria
  • Willing to participate in a study
  • Others
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT01196923
25-2858
Not Provided
Not Provided
Not Provided
CardioFocus
CardioFocus
Not Provided
Study Director: Burke Barrett CardioFocus
CardioFocus
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP